top of page


In the current cancer immunotherapy field, the remarkable new approaches such as antibody drugs and checkpoint inhibitors have been progressed. On the other hand, not all of them have been proven to be effective against all cancer diseases. There are many types of cancers with unmet medical needs for which no definitive treatment has yet been established, and there is a need for new drugs and treatment methods. Although there are methods of cancer immunotherapy using the patient's own cells to activate the body's immune cells nonspecifically or only for the limited tumor antigens, such methods have not solved the problems of limited therapeutic effects and low durability. It is known that the ultimate cancer immunotherapy is a method for the establishment of immunological memory against cancer in the tumor-specific manner. In another word, patients acquiring immune cells that have memorized the cancer can attack again even if the cancer recurs. Our SynVC is an innovative therapy that enables patients to acquire tumor antigen-specific cancer immunity by presenting all tumor antigens possessed by the patient's own tumor cells and tissues to the immune cells in the patient's body, which then memorize them. Since the patient's own cells can be processed and treated rapidly in a short period of time, we believe that the treatment with SynVC is safe and effective for patients with all types of cancer and at any stage of life.

Yasuyuki ISHII PhD



Company Profile

Company Name  Accellvecs Inc.


Office  1-12-8, Shibuya, Shibuya-ku, Tokyo, 150-0002, Japan

Representative  President & CEO Yasuyuki Ishii

Contact Us

Contact Form

bottom of page